Innoviva Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
465,125.00
240,498.00
187,283.00
150,433.00
129,075.00
114,908
Total Accounts Receivable
3,380.00
10,550.00
26,228.00
46,847.00
70,540.00
83,286
Inventories
10,406.00
-
-
-
-
-
Other Current Assets
4,287.00
1,134.00
814.00
766.00
754.00
849
Total Current Assets
483,198.00
252,182.00
214,325.00
198,046.00
200,369.00
199,043
Net Property, Plant & Equipment
10,238.00
324.00
221.00
368.00
209.00
160
Total Investments and Advances
56,207.00
42,856.00
-
-
-
-
Intangible Assets
124,257.00
208,191.00
-
-
-
-
Other Assets
7,355.00
18,101.00
194,386.00
180,582.00
166,759.00
152,936
Total Assets
681,255.00
521,654.00
408,932.00
378,996.00
367,337.00
548,193
ST Debt & Current Portion LT Debt
-
-
-
7,752.00
25,000.00
Accounts Payable
47,583.00
1,056.00
818.00
128.00
601.00
Other Current Liabilities
36,821.00
12,700.00
12,673.00
12,169.00
9,141.00
Total Current Liabilities
84,404.00
13,756.00
13,491.00
20,049.00
34,742.00
Long-Term Debt
287,500.00
725,636.00
733,131.00
708,341.00
574,362.00
Other Liabilities
10,229.00
5,611.00
4,955.00
3,597.00
940.00
Total Liabilities
382,133.00
745,003.00
751,577.00
731,987.00
610,044.00
Common Equity (Total)
299,122.00
223,349.00
342,645.00
352,991.00
242,859.00
Total Shareholders' Equity
299,122.00
223,349.00
342,645.00
352,991.00
242,859.00
Total Equity
299,122.00
223,349.00
342,645.00
352,991.00
242,707.00
Liabilities & Shareholders' Equity
681,255.00
521,654.00
408,932.00
378,996.00
367,337.00
Accumulated Minority Interest
-
-
-
-
152.00

About Innoviva

View Profile
Address
2000 Sierra Point Parkway
Brisbane California 94005
United States
Employees -
Website http://www.inva.com
Updated 07/08/2019
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P.